Какова рыночная капитализация для Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Рыночная капитализация для Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) Это $5.17B

Прибыль Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Q: Какова цена за Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Цена за Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) Это $4.64

Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.

Год	Прибыль	Изменить
Недостаточно данных для указанных дат.

Год

Прибыль

Изменить

Недостаточно данных для указанных дат.

Компания	Прибыль	Разница в прибыли	Страна
Intuitive Surgical, Inc. ISRG.US	$3.81B	-	US
EssilorLuxottica S.A. EL.PA	$4.11B	-	FR
HOYA Corporation 7741.T	-	-	JP
Becton, Dickinson and Company BDX.US	$1.59B	-	US
Alcon Inc. ALC.SW	-	-	CH

Компания

Прибыль

Разница в прибыли

Страна